CTV vs. Online Video for Pharma: How to Allocate the Roles
Compare CTV and online video for pharma by viewing environment, targeting, creative, supply, frequency, action, and measurement.
The short answer
Use CTV for television-screen reach and longer-form sight, sound, and motion when the creative and supply support it. Use online video for broader device coverage, contextual precision, sequenced messaging, and more immediate interaction. Allocate around those jobs, then test incremental reach and outcomes.
Compare the environments
| Dimension | CTV | Online video |
|---|---|---|
| Typical screen | Television | Mobile, desktop, tablet, web/app |
| Interaction | Limited | Click or page action often possible |
| Identity | Often household/account | Device, cookie, login, or modeled person |
| Supply risk | App/channel and reseller opacity | Placement quality and instream classification |
| Frequency | Fragmented across apps and buys | Fragmented across browsers/platforms |
| Creative | TV-like duration and format | Multiple lengths and placements |
These are tendencies, not guarantees. Validate actual placement and device reporting.
Assign channel jobs
Possible jobs include broad eligible reach, target-list extension, disease education, retargeted sequence, site action, or launch burst. One channel may do several jobs, but each plan cell needs a primary one and a success measure aligned to it.
FDA guidance on benefit-risk presentation applies to prescription-drug promotion across media; format constraints do not remove the need for truthful, non-misleading, balanced presentation (FDA). Promotional-review teams decide execution details.
Measure incremental contribution
Deduplicate reach on the most defensible common identity unit. Compare quality, audience composition, and marginal cost. Click rates should not decide CTV value, and completion rates should not substitute for business outcomes in either channel.
Hypothetical allocation test
A base OLV plan reaches 300,000 eligible households. Adding CTV reaches 90,000 more at acceptable quality, while shifting the same money within OLV adds only 35,000. CTV has stronger marginal reach in this scenario, but the outcome and cost evidence still matter. Figures are illustrative.
When the answer changes
CTV may be constrained by approved creative, addressable scale, or measurement coverage. OLV may suffer from poor placement transparency or sound-off viewing. Small HCP audiences can saturate quickly in either channel. Reassess by audience and supply path, not by industry average.
Practical takeaway
Give each video channel a measurable job and compare marginal contribution. The next step is a channel-role matrix specifying audience, environment, creative, frequency unit, quality gate, and outcome for every video line.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.